Abstract
Although cognitive behavioral therapy (CBT) is a generally effective treatment for treating anxiety disorders, there is clearly still room for further improvements. Recent advances in neuroscience of extinction learning led to novel clinical strategies to augment exposure-based treatments with d-cycloserine (DCS), a partial agonist at the glycine recognition site of the glutamatergic N-methyl-d-aspartate receptor. This review provides an update on the current knowledge of DCS as an augmentation strategy of CBT for anxiety disorders. The adequacy of the CBT to be augmented, the dose of DCS, and the timing and duration of augmentation efforts all appear to be important moderating variables. Moreover, there is evidence that DCS may also augment fear memory reconsolidation if the fear level remains high after the exposure. Future studies need to examine whether DCS can augment CBT when administered after exposure in order to develop a tailored administration strategy to maximize its clinical utility.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Hofmann SG, Asnaani A, Vonk JJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Therapy Res. 2012;36:427–40.
Simos G, Hofmann SG. CBT for anxiety disorders: a practitioner book. Chichester: Wiley-Blackwell; 2013.
Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60:369–75.
Hofmann SG, Wu QJ, Boettcher H. D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord. 2013;3:11. Reviews the current preclinical and clinical literature of DCS as an augmentation strategy for CBT.
Hofmann SG, Sawyer AT, Asnaani A. D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders: an update. Curr Pharm Des. 2012;18:5659–62.
Hofmann SG, Fang A, Gutner CA. Cognitive enhancers for the treatment of anxiety disorders. Restor Neurol Neurosci. 2014;32:183–95. Reviews candidate agents that may act as a cognitive enhancers for psychological treatments of anxiety disorders.
Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136–44.
Hofmann SG, Meuret AE, Smits JAJ, et al. Augmentation of exposure therapy for social anxiety disorder with d-cycloserine. Arch Gen Psychiatry. 2006;63:298–304.
Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63:544–9.
Otto MW, Tolin DF, Simon NM, et al. The efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2009;67:365–70.
Siegmund A, Golfels F, Finck C, Halisch A, Räth D, Plag J, et al. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011;45:1042–7.
Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62:835–8.
Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165:335–41.
Storch EA, Murphy TK, Goodman WK, et al. A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010;68:1073–6.
Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem. 2004;11:510–6.
Litz BT, Salters-Pedneault K, Steenkamp M, Hermos JA, Bryant RA, Otto MW, et al. A randomized placebo-controlled trial of d-cycloserine and exposure therapy for post-traumatic stress disorder. J Psychiatr Res. 2012;46:1184–90.
Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry. 2014;171:640–8.
Hofmann SG, Smits AJ, Rosenfield D, Simon NM, Otto MW, Meuret AE, et al. D-cycloserine as an augmentation strategy of cognitive behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013;170:751–8. Presents the largest clinical trial of DCS as an augmentation strategy for CBT of social anxiety disorder to date.
Popik P, Wrobel M, Nowak G. Chronic treatment with antidepressants affect glycine/NMDA receptor function: behavioral evidence. Neuropharmacology. 2000;39:2278–87.
Lee JL, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci. 2006;26:10051–6.
Hofmann SG. D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety. 2014;31:175–7. Provides a concise review of the clinical evidence suggesting that DCS can augment extinction learning, as well as augment fear memory reconsolidation.
Bouton ME, Vurbic D, Woods AM. D-cycloserine facilitates context-specific fear extinction learning. Neurobiol Learn Mem. 2008;90:504–10.
Smits JAJ, Rosenfield D, Otto MW, Marques L, Davis ML, Meuret AE, et al. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013;47:1455–81.
Smits JAJ, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, et al. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry. 2013;73:1054–8.
Tart CD, Handelsman P, DeBoer LB, Rosenfield D, Pollack MH, Hofmann SG, et al. Augmentation of exposure therapy with post-session administration of d-cycloserine. J Psychiatr Res. 2013;47:168–74.
Anderson KC, Insel TR. The promise of extinction research for the prevention and treatment of anxiety disorders. Biol Psychiatry. 2006;60:319–21.
Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci. 2003;117:341–9.
Rodebaugh TL, Levinson CA, Lenze EJ. A high-throughput clinical assay for testing drug facilitation of exposure therapy. Depress Anxiety. 2013;30:631–7.
Smits JAJ, Hofmann SG, Rosenfield D, DeBoer LB, Costa P, Simon NM, et al. D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol. 2013;81:1100–12.
de Kleine RA, Hendriks GJ, Smits JA, Broekman TG, van Minnen A. Prescriptive variables for d-cycloserine augmentation of exposure therapy for posttraumatic stress disorder. J Psychiatr Res. 2014;48:40–6.
Smits JA, Rosenfield D, Davis ML, Julian K, Handelsman PR, Otto MW, et al. Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. Biol Psychiatry. 2014;75:840–6.
Soravia LM, Heinrichs M, Winzeler L, Fisler M, Schmitt W, Horn H, et al. Glucocorticoids enhance in vivo exposure-based therapy of spider phobia. Depress Anxiety. 2014;31:429–35.
Acknowledgments
Dr. Hofmann’s work is supported by NIH grant R01AT007257 and R34MH099311. Dr. Smits’s work is supported by NIH grants R34MH099318, R34DA031038, R01DA027533, and R34DA034658.
Compliance with Ethics Guidelines
ᅟ
Conflict of Interest
Stefan G. Hofmann serves on the Advisory Board of Otsuka America Pharmaceutical, Inc., and receives financial compensation for his participation as an advisor.
Jasper A. Smits declares no conflict of interest.
Michael W. Otto receives payment as consultant from ProPhase, MicroTransponder, and Concert Pharmaceuticals and royalties for use of the SIGH-A.
Mark H. Pollack is on the advisory boards and provides consultation for Concert Pharmaceuticals, Edgemont Pharmaceuticals, Ironwood Pharmaceuticals, Palo Alto Health Sciences, Project Plus. He receives equity from Doyen Medical, Medavante, Mensante Corporation, Mindsite, Targia Pharmaceuticals and royalty/patent payment for the SIGH-A, SAFER interviews.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Anxiety Disorders
Rights and permissions
About this article
Cite this article
Hofmann, S.G., Otto, M.W., Pollack, M.H. et al. d-Cycloserine Augmentation of Cognitive Behavioral Therapy for Anxiety Disorders: an Update. Curr Psychiatry Rep 17, 532 (2015). https://doi.org/10.1007/s11920-014-0532-2
Published:
DOI: https://doi.org/10.1007/s11920-014-0532-2